Skip to main content

Table 3 Best-fitted vaccine efficacy profiles for the 6–12 weeks and 5–17 months cohorts when fitting to 3-month incidence data from the RTS,S Phase III trial

From: The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease

Cohort Initial efficacy against infection at completion of 3rd dose (%) Half-life of efficacy against infection (months) Decay (Weibull decay shape parameter) Boosting efficacy against infection at 4th dose (%)
Exponential decay
 6–12 weeks 57.5 (95 % CI 40.1–71.2) 7.4 (95 % CI 6.1–10.4) Exponential 48.5 (95 % CI 32.8–64.3)
 5–17 months 72.5 (95 % CI 57.7–83.7) 7.9 (95 % CI 6.1–11.0) Exponential 39.2 (95 % CI 30.6–53.4)
Weibull decay
 6–12 weeks 64.9 (95 % CI 44.0–83.2) 7.2 (95 % CI 6.0–9.8) 0.84 (95 % CI 0.64–0.99) 55.2 (95 % CI 34.5–73.1)
 5–17 months 91.1 (95 % CI 74.5–99.7) 7.32 (95 % CI 6.0–10.0) 0.69 (95 % CI 0.54–0.9) 49 (95 % CI 32–68.6)
  1. Posterior distributions described by mean and 95 % credible interval